?
Murphy Andrew J
EVP Research
Regeneron Pharmaceuticals, Inc.
US, Tarrytown [HQ]
CIK
1796226
Data Source
We automatically created this profile. The information was aggregated based on earnings call transcripts, insider forms and DEF 14A statements.
Latest Information
Shares :
47,121
Price per Share :
$703.43
Equivalence :
$33,146,325.03
Transaction History
-
G47,121 Shares After TransactionValue : $n/a$0.0Transaction Date : 11/08/24
-
Footnotes
-
-
Footnotes:No footnote found.
-
A50,620 Shares After TransactionValue : $n/a$0.0Transaction Date : 12/06/24
-
Footnotes
-
-
Footnotes:#1 Award of Restricted Stock under the Second Amended and Restated 2014 Long-Term Incentive Plan that vests 50% on December 6, 2026 and 50% on December 6, 2028.
-
F50,128 Shares After TransactionValue : $39,450,736.00$387,204.00Transaction Date : 12/09/24
-
Footnotes
-
-
Footnotes:#1 Award of Restricted Stock under the Second Amended and Restated 2014 Long-Term Incentive Plan that vests 50% on December 6, 2026 and 50% on December 6, 2028.
-
F49,074 Shares After TransactionValue : $35,863,769.94$770,273.74Transaction Date : 12/16/24
-
Footnotes
-
-
Footnotes:No footnote found.
-
M68,306 Shares After TransactionValue : $27,299,175.96$7,993,200.00Transaction Date : 03/13/24
-
Footnotes
-
-
Footnotes:#1 Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 9, 2023.#2 Represents volume-weighted average price of sales of 182 shares of Company stock on March 14, 2024 at prices ranging from $951.89 to $951.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 14, 2024 at each separate price.#3 Represents volume-weighted average price of sales of 444 shares of Company stock on March 14, 2024 at prices ranging from $952.00 to $952.73. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 14, 2024 at each separate price.